{"id":"hepavax-gene","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4298008","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine candidate uses recombinant DNA or gene-based technology to express hepatitis B antigens and stimulate both cellular and humoral immune responses. It is intended to provide therapeutic benefit in patients with chronic hepatitis B infection by enhancing immune control of the virus, rather than serving as a preventive vaccine for naive populations.","oneSentence":"Hepavax-Gene is a therapeutic hepatitis B vaccine designed to generate immune responses against hepatitis B virus through genetic engineering approaches.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:01.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT02713620","phase":"PHASE4","title":"Hepatitis B Vaccination in HIV-infected Adults","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2015-01","conditions":"Hepatitis B","enrollment":154},{"nctId":"NCT01349283","phase":"PHASE3","title":"Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-05","conditions":"Hepatitis B","enrollment":1738},{"nctId":"NCT01289106","phase":"PHASE3","title":"Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2011-01","conditions":"HIV Infection","enrollment":132}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CEREBRAL VENTRICLE DILATATION"},{"count":1,"reaction":"CLONIC CONVULSION"},{"count":1,"reaction":"ELECTROLYTE IMBALANCE"},{"count":1,"reaction":"HYDROCEPHALUS"},{"count":1,"reaction":"HYPERKALAEMIA"},{"count":1,"reaction":"RETINOPATHY OF PREMATURITY"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Berna"],"phase":"phase_3","status":"active","brandName":"Hepavax-Gene","genericName":"Hepavax-Gene","companyName":"Chiang Mai University","companyId":"chiang-mai-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hepavax-Gene is a therapeutic hepatitis B vaccine designed to generate immune responses against hepatitis B virus through genetic engineering approaches. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}